Skip to content
tupungato
- Cassava Sciences (NASDAQ:SAVA) has formally ended its phase 3 REFOCUS-ALZ trial for Alzheimer’s asset simufilam.
- The development was made on the ClinicalTrials.gov website, which states it was a sponsor decision.
- Cassava’s action wasn’t much of a surprise considering the company